WHO ICTRP trial
REYAGEN study. Optimization of unboosted atazanavir dosing, when associated with…
EUCTR2009-014216-35-IT · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2009-014216-35-IT |
|---|---|
| Public title | REYAGEN study. Optimization of unboosted atazanavir dosing, when associated with tenofovir, guided by pharmacogenetics profile of HIV-patients - ND |
| Scientific title | REYAGEN study. Optimization of unboosted atazanavir dosing, when associated with tenofovir, guided by pharmacogenetics profile of HIV-patients - ND |
| Primary sponsor | AZIENDA SANITARIA LOCALE 4 DI TORINO |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Italy |
| Conditions | HIV infection MedDRA version: 9.1 Level: PT Classification code 10020161 |
| Interventions | Pharmaceutical Form: Capsule, hard INN or Proposed INN: Atazanavir Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- |
| Registration date | Apr 11, 2009 |
| Secondary IDs | PG001 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: